A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology.
Yuxia LinMona KhanBirgit WeynandManon LaporteFrank CoenjaertsDarius BabusisJohn P BilelloPeter MombaertsDirk JochmansJohan NeytsPublished in: Nature communications (2024)
Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory tract infections. There are no convenient small-animal infection models. Here, we show viral replication in the upper and lower airways of AG129 mice (double IFNα/β and IFNγ receptor knockout mice) upon intranasal inoculation. By multiplex fluorescence RNAscope and immunohistochemistry followed by confocal microscopy, we demonstrate viral tropism to ciliated cells and club cells of the bronchiolar epithelium. HPIV-3 causes a marked lung pathology. No virus transmission of the virus was observed by cohousing HPIV-3-infected AG129 mice with other mice. Oral treatment with GS-441524, the parent nucleoside of remdesivir, reduced infectious virus titers in the lung, with a relatively normal histology. Intranasal treatment also affords an antiviral effect. Thus, AG129 mice serve as a robust preclinical model for developing therapeutic and prophylactic strategies against HPIV-3. We suggest further investigation of GS-441524 and its prodrug forms to treat HPIV-3 infection in humans.
Keyphrases
- high fat diet induced
- induced apoptosis
- respiratory tract
- mouse model
- quantum dots
- cell cycle arrest
- sars cov
- immune response
- dendritic cells
- endothelial cells
- signaling pathway
- insulin resistance
- type diabetes
- endoplasmic reticulum stress
- cystic fibrosis
- wild type
- high glucose
- disease virus
- metabolic syndrome
- adipose tissue
- drug delivery
- combination therapy
- single molecule
- replacement therapy